Related content

A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker

By Carlet J.  

Intensive Care Medicine, Vol. 30, Iss. 5, 2004-05 ,pp. : 994-994

Springer Publishing Company

Access to resources Recommend Favorite

Goal Attainment Scaling in the Evaluation of Treatment of Upper Limb Spasticity with Botulinum Toxin: A Secondary Analysis from a Double-blind Placebo-Controlled Randomized Clinical Trial

By Turner-Stokes Lynne   Baguley Ian J.   De Graaff Stephen   Katrak Pesi   Davies Leo   McCrory Paul   Hughes Andrew  

Journal of Rehabilitation Medicine, Vol. 42, Iss. 1, 2010-01 ,pp. : 81-89

Medical Journals Limited

Access to resources Recommend Favorite

Analysis of randomized comparative clinical trial data for personalized treatment selections

By Cai Tianxi   Tian Lu   Wong Peggy H.   Wei L. J.  

Biostatistics, Vol. 12, Iss. 2, 2011-04 ,pp. : 270-282

Oxford University Press

Access to resources Recommend Favorite

Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial

By Marco Ester   Duarte Esther   Vila Joan   Tejero Marta   Guillen Anna   Boza Roser   Escalada Ferran   Espadaler Josep M.  

Journal of Rehabilitation Medicine, Vol. 39, Iss. 6, 2007-07 ,pp. : 440-447

Medical Journals Limited

Access to resources Recommend Favorite

Efficacy and Safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial – an Indian experience

By Kumar Das Siddharth   Pareek Anil   Mathur D. S.   Wanchu Ajay   Srivastava Ragini   Agarwal G. G.   Chauhan R. S.  

Current Medical Research and Opinion, Vol. 23, Iss. 9, 2007-09 ,pp. : 2227-2234

Informa Healthcare

Access to resources Recommend Favorite